Navigation For Mobile

Category Archives: drugs

The Growing Impact of Rare Disease Drugs

AstraZeneca’s $39-billion acquisition of Alexion Pharmaceuticals  joined by Merck’s acquisition of Acceleron for $11.5 billion and other deals, have made the Rare Disease space a destination for Big Pharma this…

Posted in drug discovery, drugs, FDA, Orphan drug | Tagged , | Comments Off on The Growing Impact of Rare Disease Drugs

Deuterated Drug Molecules: Perfecting the Gamechanger

Scientific breakthroughs in the pharmaceutical industry can happen overnight, but it still takes time to perfect a discovery’s applications. Deuterium-labeled active pharmaceutical ingredients (APIs) are one specific advancement that has…

Posted in APIs, deuterated molecule, deuteration, deuterium exchange, drugs | Tagged , , | Comments Off on Deuterated Drug Molecules: Perfecting the Gamechanger

Pharma 2020-2021: Much More Than Just COVID

Set aside ‘Everything-COVID,’ and to many outsiders the past 20 months can appear as though the pharmaceutical industry took a sabbatical. Not true, of course…but everything else that occurred in…

Posted in Chemistry, COVID19, drug discovery, drugs, Industry news, R&D, supply chain | Comments Off on Pharma 2020-2021: Much More Than Just COVID

What Lessons Has Pharma Learned From COVID?

There’s an eye-popping amount of good news for pharma floating around out there. One report claims a ‘Golden decade of unbelievable innovation’ lies ahead. Others point to COVID19 as the…

Posted in Contract Manufacturing, COVID19, drug discovery, drugs, R&D, regulatory | Comments Off on What Lessons Has Pharma Learned From COVID?

What are Some of the Key Trends in Analytical R&D Labs?

Five years ago this month, we published a post on emerging analytical R&D trends, discussing key techniques such as Multi-Dimensional Liquid Chromatography, Hyphenated Mass Spectrometric Techniques, Error Analysis, Semi-Micro Methacrylate…

Posted in analytical science, drugs | Tagged , , , | Comments Off on What are Some of the Key Trends in Analytical R&D Labs?

How CMO Expertise Can Solve Key Challenges in Late Phase Drug API Projects

Stating the obvious here, but drug development is a protracted, expensive and risky process. From the lab bench to pharmacy shelves, bringing a new drug to market often stretches 10+…

Posted in APIs, Capabilities, Chemistry, CMC, Contract Manufacturing, CRO/CMO, drugs, method development, Neuland Labs, outsourcing, process chemistry, Process Engineering, scale-up | Tagged , , , , | Comments Off on How CMO Expertise Can Solve Key Challenges in Late Phase Drug API Projects

Small Pharma Steps Up

Here’s some good news, courtesy of DCAT Value Chain Insights: “Smaller bio/pharmaceutical companies are accounting for an increasingly larger portion of new products as measured by recent new molecular entity…

Posted in drug discovery, drugs, FDA | Tagged , , , , | Comments Off on Small Pharma Steps Up

Blockbuster Drugs Hang On: Is a Post-Blockbuster World in Sight Yet?

“Blockbuster” drugs — typically defined as those that generate annual sales of $1 billion or more — have been the lifeblood of Big Pharma company revenues since Smith, Kline and French’s…

Posted in blockbuster, drugs | Tagged , , , | Comments Off on Blockbuster Drugs Hang On: Is a Post-Blockbuster World in Sight Yet?

Generic Drug Opportunities in Global Markets

Generic drugs have moved quickly over the last 30 years into a position of dominance in drug markets around the world. In 2018, generic drug savings totaled $293 billion in…

Posted in APIs, drugs, generic | Tagged , , | Comments Off on Generic Drug Opportunities in Global Markets

Earth Day 2021: Reinventing Business As Usual

April 22 is Earth Day and this year’s theme is Restore our Earth. On their website, Earthday.org states “When life around the globe returns to normal, our world cannot return…

Posted in atom economy, Chemistry, corporate stewardship, drugs, Effluent, EHS, energy conservation, energy effciency, green chemistry | Tagged , , , , | Comments Off on Earth Day 2021: Reinventing Business As Usual